688091 上海谊众
已收盘 08-28 15:00:00
资讯
新帖
简况
上海谊众（688091）披露将参加科创板2026年半年度创新药行业集体业绩说明会，8月28日股价下跌6.36%
证券之星 · 08-28 22:21
上海谊众（688091）披露将参加科创板2026年半年度创新药行业集体业绩说明会，8月28日股价下跌6.36%
8月27日上海谊众（688091）龙虎榜数据：北向资金净买入4795.37万元
证券之星 · 08-27 17:53
8月27日上海谊众（688091）龙虎榜数据：北向资金净买入4795.37万元
8月27日上海谊众涨16.42%，太平科创精选混合发起式A基金重仓该股
证券之星 · 08-27 16:43
8月27日上海谊众涨16.42%，太平科创精选混合发起式A基金重仓该股
股市必读：上海谊众新发布《上海谊众药业股份有限公司2026年半年度报告摘要》
证券之星 · 08-27 05:14
股市必读：上海谊众新发布《上海谊众药业股份有限公司2026年半年度报告摘要》
上海谊众（688091）披露2026年半年度报告，8月25日股价下跌0.43%
证券之星 · 08-25
上海谊众（688091）披露2026年半年度报告，8月25日股价下跌0.43%
图解上海谊众中报：第二季度单季净利润同比增长1.34%
证券之星 · 08-25
图解上海谊众中报：第二季度单季净利润同比增长1.34%
上海谊众(688091)6月30日股东户数0.99万户，较上期增加4.97%
证券之星 · 08-25
上海谊众(688091)6月30日股东户数0.99万户，较上期增加4.97%
8月24日上海谊众跌7.65%，太平科创精选混合发起式A基金重仓该股
证券之星 · 08-24
8月24日上海谊众跌7.65%，太平科创精选混合发起式A基金重仓该股
每周股票复盘：上海谊众（688091）两款创新药获临床试验批准
证券之星 · 08-23
每周股票复盘：上海谊众（688091）两款创新药获临床试验批准
8月20日上海谊众涨7.14%，太平科创精选混合发起式A基金重仓该股
证券之星 · 08-20
8月20日上海谊众涨7.14%，太平科创精选混合发起式A基金重仓该股
股市必读：上海谊众新发布《上海谊众药业股份有限公司关于在研创新药YXC-002获得药物临床试验批准通知书的自愿性披露公告》
证券之星 · 08-20
股市必读：上海谊众新发布《上海谊众药业股份有限公司关于在研创新药YXC-002获得药物临床试验批准通知书的自愿性披露公告》
股市必读：上海谊众新发布《上海谊众药业股份有限公司关于在研创新药YXC-001获得药物临床试验批准通知书的自愿性披露公告》
证券之星 · 08-19
股市必读：上海谊众新发布《上海谊众药业股份有限公司关于在研创新药YXC-001获得药物临床试验批准通知书的自愿性披露公告》
上海谊众最新公告：在研创新药YXC-002获临床试验批准
证券之星 · 08-18
上海谊众最新公告：在研创新药YXC-002获临床试验批准
上海谊众（688091）披露在研创新药YXC-001获得药物临床试验批准通知书，8月17日股价上涨1.75%
证券之星 · 08-17
上海谊众（688091）披露在研创新药YXC-001获得药物临床试验批准通知书，8月17日股价上涨1.75%
股市必读：上海谊众新发布《上海谊众药业股份有限公司第三届董事会第五次会议决议公告》
证券之星 · 08-10
股市必读：上海谊众新发布《上海谊众药业股份有限公司第三届董事会第五次会议决议公告》
每周股票复盘：上海谊众（688091）拟用3.9亿闲置募资现金管理
证券之星 · 08-09
每周股票复盘：上海谊众（688091）拟用3.9亿闲置募资现金管理
股市必读：上海谊众新发布《上海谊众药业股份有限公司关于股份回购的进展公告》
证券之星 · 08-05
股市必读：上海谊众新发布《上海谊众药业股份有限公司关于股份回购的进展公告》
上海谊众（688091）披露股份回购进展公告，8月3日股价上涨4.08%
证券之星 · 08-03
上海谊众（688091）披露股份回购进展公告，8月3日股价上涨4.08%
股市必读：上海谊众新发布《上海谊众药业股份有限公司关于实际控制人增持公司股份的公告》
证券之星 · 08-03
股市必读：上海谊众新发布《上海谊众药业股份有限公司关于实际控制人增持公司股份的公告》
上海谊众（688091）披露实际控制人增持公司股份公告，7月30日股价下跌2.88%
证券之星 · 07-30
上海谊众（688091）披露实际控制人增持公司股份公告，7月30日股价下跌2.88%
公司概况
公司名称：
上海谊众药业股份有限公司
所属行业：
医药制造业
上市日期：
2021-09-09
主营业务：
上海谊众药业股份有限公司的主营业务是抗肿瘤创新药及相关产品的开发。公司的主要产品是抗肿瘤2类新药“注射用紫杉醇聚合物胶束”。
发行价格：
38.10
{"stockData":{"symbol":"688091","market":"SH","secType":"STK","nameCN":"上海谊众","latestPrice":40.5,"timestamp":1787900400000,"preClose":43.25,"halted":0,"volume":6640252,"delay":0,"changeRate":-0.0636,"floatShares":206999999,"shares":206999999,"eps":0.3332,"marketStatus":"已收盘","change":-2.75,"latestTime":"08-28 15:00:00","open":42.47,"high":42.77,"low":40.01,"amount":273000000,"amplitude":0.0638,"askPrice":40.5,"askSize":390,"bidPrice":40.46,"bidSize":563,"shortable":0,"etf":0,"ttmEps":0.3332,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":5,"adr":0,"adjPreClose":43.25,"symbolType":"stock_kcb","openAndCloseTimeList":[[1787880600000,1787887800000],[1787893200000,1787900400000]],"highLimit":47.58,"lowLimit":38.93,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":206703640,"isCdr":false,"pbRate":5.62,"roa":"--","peRate":121.548619,"roe":"2.91%","epsLYR":0.32,"committee":0.179688,"marketValue":8371000000,"turnoverRate":0.0321,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-08-31。","afterMarket":{"amount":67230,"volume":1660,"close":40.5,"buyVolume":2421,"sellVolume":0,"time":1787902437746,"indexStatus":"已收盘 08-28 15:30:00","preClose":43.25},"floatMarketCap":8371000000},"requestUrl":"/m/hq/s/688091/wiki","defaultTab":"wiki","newsList":[{"id":"2662099745","title":"上海谊众（688091）披露将参加科创板2026年半年度创新药行业集体业绩说明会，8月28日股价下跌6.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662099745","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662099745?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:21","pubTimestamp":1787926908,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，上海谊众报收于40.5元，较前一交易日下跌6.36%，最新总市值为83.71亿元。该股当日开盘42.47元，最高42.77元，最低40.01元，成交额达2.73亿元，换手率为3.22%。公告显示，公司将于2026年9月16日15:00-17:00参加科创板2026年半年度创新药行业集体业绩说明会，通过上证路演中心网络互动方式，就公司2026年半年度经营成果、财务状况等与投资者进行交流。投资者可于2026年9月9日至9月15日16:00前通过上证路演中心网站或公司邮箱提交问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800054699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK0239","688091","BK1574","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662377000","title":"8月27日上海谊众（688091）龙虎榜数据：北向资金净买入4795.37万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662377000","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662377000?lang=zh_cn&edition=full","pubTime":"2026-08-27 17:53","pubTimestamp":1787824403,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年8月27日公布的交易公开信息显示，上海谊众因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年8月27日收盘，上海谊众报收于43.25元，上涨16.42%，换手率5.56%，成交量11.45万手，成交额4.71亿元。从龙虎榜公布的当日买卖数据来看，北向资金合计净买入4795.37万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700042139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688091"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662774910","title":"8月27日上海谊众涨16.42%，太平科创精选混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662774910","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662774910?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:43","pubTimestamp":1787820202,"startTime":"0","endTime":"0","summary":"证券之星消息，8月27日上海谊众涨16.42%，收盘报43.25元，换手率5.56%，成交量11.45万手，成交额4.71亿元。重仓上海谊众的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为太平基金的太平科创精选混合发起式A。太平科创精选混合发起式A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700038991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688091","159982","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662322747","title":"股市必读：上海谊众新发布《上海谊众药业股份有限公司2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662322747","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662322747?lang=zh_cn&edition=full","pubTime":"2026-08-27 05:14","pubTimestamp":1787778854,"startTime":"0","endTime":"0","summary":"公司公告汇总上海谊众药业股份有限公司2026年半年度报告摘要截至2026年6月30日，公司总资产1,604,455,165.20元，归母净资产1,490,602,334.82元，较上年度末分别增长5.07%和4.22%。上海谊众药业股份有限公司第三届董事会第六次会议决议公告2026年8月25日召开第三届董事会第六次会议，审议通过2026年半年度报告及摘要、半年度募集资金存放与实际使用情况专项报告、“提质增效重回报”行动方案半年度评估报告、向2026年限制性股票激励计划激励对象授予预留部分限制性股票等事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700010200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688091","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662587767","title":"上海谊众（688091）披露2026年半年度报告，8月25日股价下跌0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662587767","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662587767?lang=zh_cn&edition=full","pubTime":"2026-08-25 22:27","pubTimestamp":1787668050,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，上海谊众报收于36.8元，较前一交易日下跌0.43%，最新总市值为76.07亿元。该股当日开盘36.88元，最高37.26元，最低36.13元，成交额达1.41亿元，换手率为1.86%。近日，上海谊众药业股份有限公司披露2026年半年度报告。公告显示，截至报告期末，公司总资产为1,604,455,165.20元，归属于上市公司股东的净资产为1,490,602,334.82元，分别较上年度末增长5.07%和4.22%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500050911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688091"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662735178","title":"图解上海谊众中报：第二季度单季净利润同比增长1.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662735178","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662735178?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:33","pubTimestamp":1787653994,"startTime":"0","endTime":"0","summary":"证券之星消息，上海谊众2026年中报显示，上半年度公司主营收入1.66亿元，同比上升3.45%；归母净利润4230.36万元，同比上升11.31%；扣非净利润3808.93万元，同比上升2.79%；其中2026年第二季度，公司单季度主营收入8667.8万元，同比下降2.91%；单季度归母净利润2413.6万元，同比上升1.34%；单季度扣非净利润2153.8万元，同比下降1.92%；负债率7.1%，投资收益213.14万元，财务费用-661.82万元，毛利率85.22%。财报数据概要请见下图:本文数据来源于上海谊众2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500039329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688091"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662386077","title":"上海谊众(688091)6月30日股东户数0.99万户，较上期增加4.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662386077","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662386077?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:40","pubTimestamp":1787650843,"startTime":"0","endTime":"0","summary":"证券之星消息，近日上海谊众披露，截至2026年6月30日公司股东户数为9868.0户，较3月31日增加467.0户，增幅为4.97%。在化学制药行业个股中，上海谊众股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.68万户。从股价来看，2026年3月31日至2026年6月30日，上海谊众区间跌幅为29.47%，在此期间股东户数增加467.0户，增幅为4.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500036783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688091","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661212352","title":"8月24日上海谊众跌7.65%，太平科创精选混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661212352","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661212352?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:33","pubTimestamp":1787560384,"startTime":"0","endTime":"0","summary":"证券之星消息，8月24日上海谊众跌7.65%，收盘报36.96元，换手率2.59%，成交量5.34万手，成交额2.03亿元。重仓上海谊众的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为太平基金的太平科创精选混合发起式A。太平科创精选混合发起式A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400021819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688091","BK0239","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661214380","title":"每周股票复盘：上海谊众（688091）两款创新药获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2661214380","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661214380?lang=zh_cn&edition=full","pubTime":"2026-08-23 03:20","pubTimestamp":1787426420,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，上海谊众报收于40.02元，较上周的41.18元下跌2.82%。本周，上海谊众8月20日盘中最高价报43.81元。本周关注点来自公司公告汇总：在研创新药YXC-001获临床试验批准，用于晚期实体瘤治疗。公司公告汇总上海谊众药业股份有限公司全资子公司上海佑希创医药科技有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，其自主研发的创新药YXC-001用于晚期实体瘤治疗的临床试验申请已获批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1161","159992","BK1574","688091","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660024514","title":"8月20日上海谊众涨7.14%，太平科创精选混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660024514","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660024514?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:36","pubTimestamp":1787214977,"startTime":"0","endTime":"0","summary":"证券之星消息，8月20日上海谊众涨7.14%，收盘报42.48元，换手率4.14%，成交量8.54万手，成交额3.65亿元。重仓上海谊众的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为太平基金的太平科创精选混合发起式A。太平科创精选混合发起式A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000028831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159982","688091","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660995427","title":"股市必读：上海谊众新发布《上海谊众药业股份有限公司关于在研创新药YXC-002获得药物临床试验批准通知书的自愿性披露公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660995427","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660995427?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:48","pubTimestamp":1787161681,"startTime":"0","endTime":"0","summary":"公司公告汇总：自主研发创新药YXC-002片获国家药监局临床试验批准，拟用于EGFR突变非小细胞肺癌治疗。公司公告汇总上海谊众药业股份有限公司关于在研创新药YXC-002获得药物临床试验批准通知书的自愿性披露公告上海谊众药业股份有限公司自主研发的创新药YXC-002片用于治疗具有EGFR突变的非小细胞肺癌，已获得国家药品监督管理局签发的《药物临床试验批准通知书》，同意开展临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000001813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159992","BK1574","BK1161","688091","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660993454","title":"股市必读：上海谊众新发布《上海谊众药业股份有限公司关于在研创新药YXC-001获得药物临床试验批准通知书的自愿性披露公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660993454","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660993454?lang=zh_cn&edition=full","pubTime":"2026-08-19 01:11","pubTimestamp":1787073069,"startTime":"0","endTime":"0","summary":"公司公告汇总上海谊众药业股份有限公司关于在研创新药YXC-001获得药物临床试验批准通知书的自愿性披露公告上海谊众药业股份有限公司全资子公司上海佑希创医药科技有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，其自主研发的创新药YXC-001用于晚期实体瘤治疗的临床试验申请已获批准。YXC-001为First-in-Class三功能抗体融合蛋白，整合PD-1抗体、抗VEGF抗体与优化后的IL-2。临床前研究表明其在小鼠肺癌模型中疗效优于PD-1单抗及PD-1/VEGF双抗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900001253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","BK0239","06978","688091","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660464686","title":"上海谊众最新公告：在研创新药YXC-002获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660464686","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660464686?lang=zh_cn&edition=full","pubTime":"2026-08-18 19:19","pubTimestamp":1787051973,"startTime":"0","endTime":"0","summary":"上海谊众(688091.SH)公告称，公司近日收到国家药监局签发的《药物临床试验批准通知书》，自研创新药YXC-002(第四代EGFR激酶抑制剂)用于非小细胞肺癌治疗的临床试验申请已获批准。该药为第四代高脑渗透性EGFR-TKI，可靶向多种EGFR驱动基因突变和耐药突变，尤其针对C797S突变及中枢神经系统转移患者。公司提示，创新药研发周期长、风险高，临床试验进度及上市时间存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800036719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","06978","BK1574","688091","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660330794","title":"上海谊众（688091）披露在研创新药YXC-001获得药物临床试验批准通知书，8月17日股价上涨1.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660330794","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660330794?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:19","pubTimestamp":1786976392,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘，上海谊众报收于41.9元，较前一交易日上涨1.75%，最新总市值为86.61亿元。近日，上海谊众药业股份有限公司发布关于在研创新药YXC-001获得药物临床试验批准通知书的自愿性披露公告。公告显示，公司全资子公司上海佑希创医药科技有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，其自主研发的创新药YXC-001用于晚期实体瘤治疗的临床试验申请已获批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700035361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","BK1161","06978","BK0239","688091"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658608517","title":"股市必读：上海谊众新发布《上海谊众药业股份有限公司第三届董事会第五次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658608517","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658608517?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:33","pubTimestamp":1786300389,"startTime":"0","endTime":"0","summary":"公司公告汇总上海谊众药业股份有限公司第三届董事会第五次会议决议公告2026年8月6日召开第三届董事会第五次会议，审议通过公司及全资子公司使用不超过390,000,000.00元部分闲置募集资金进行现金管理的议案；资金用于购买安全性高、流动性好、保本型产品，使用期限不超过12个月，可在额度内循环滚动使用；会议应出席董事6人，实际出席6人，表决结果为赞成6票，反对0票，弃权0票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000001096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688091","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658967564","title":"每周股票复盘：上海谊众（688091）拟用3.9亿闲置募资现金管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2658967564","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658967564?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:52","pubTimestamp":1786215133,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，上海谊众报收于40.86元，较上周的36.31元上涨12.53%。本周，上海谊众8月7日盘中最高价报40.94元。本周关注点公司公告汇总：上海谊众拟使用不超过3.9亿元闲置募集资金进行现金管理。上海谊众药业股份有限公司于2026年8月6日召开第三届董事会第五次会议，审议通过公司及全资子公司使用不超过人民币390,000,000.00元的部分闲置募集资金进行现金管理的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688091"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657568145","title":"股市必读：上海谊众新发布《上海谊众药业股份有限公司关于股份回购的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657568145","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657568145?lang=zh_cn&edition=full","pubTime":"2026-08-05 01:03","pubTimestamp":1785862992,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，上海谊众报收于39.32元，上涨4.05%，换手率1.8%，成交量3.72万手，成交额1.46亿元。当日关注点交易信息汇总：8月4日主力资金净流入1582.44万元，占总成交额10.85%。公司公告汇总上海谊众药业股份有限公司关于股份回购的进展公告上海谊众药业股份有限公司于2026年7月17日至7月31日期间，通过集中竞价交易方式累计回购股份777,748股，占公司总股本的0.38%，已支付资金总额29,804,081.16元，回购价格区间为35.50元/股至40.39元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500001449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688091"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656899377","title":"上海谊众（688091）披露股份回购进展公告，8月3日股价上涨4.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656899377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656899377?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:16","pubTimestamp":1785766573,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，上海谊众报收于37.79元，较前一交易日上涨4.08%，最新总市值为78.11亿元。该股当日开盘36.3元，最高37.96元，最低36.0元，成交额达1.21亿元，换手率为1.58%。近日，上海谊众药业股份有限公司发布《关于股份回购的进展公告》。本次回购旨在维护公司价值及股东权益，符合相关法规及回购方案规定。公司将持续履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300037071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688091"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656334365","title":"股市必读：上海谊众新发布《上海谊众药业股份有限公司关于实际控制人增持公司股份的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656334365","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656334365?lang=zh_cn&edition=full","pubTime":"2026-08-03 02:46","pubTimestamp":1785696372,"startTime":"0","endTime":"0","summary":"公司公告汇总：实际控制人周劲松于7月30日增持公司股份3,000股，增持金额110,220元，增持后直接持股比例升至19.4143%。公司公告汇总上海谊众药业股份有限公司关于实际控制人增持公司股份的公告上海谊众药业股份有限公司实际控制人周劲松于2026年7月30日通过上海证券交易所集中竞价交易方式增持公司股份3,000股，约占公司总股本的0.0015%，合计增持金额110,220元。周劲松后续暂无增持计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300001089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688091"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655580543","title":"上海谊众（688091）披露实际控制人增持公司股份公告，7月30日股价下跌2.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655580543","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655580543?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:17","pubTimestamp":1785421035,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，上海谊众报收于35.74元，较前一交易日下跌2.88%，最新总市值为73.88亿元。近日，上海谊众药业股份有限公司发布《关于实际控制人增持公司股份的公告》。公告显示，公司实际控制人周劲松先生于2026年7月30日通过上海证券交易所集中竞价交易方式增持公司股份3,000股，约占公司总股本的0.0015%，合计增持金额110,220元。本次增持后，周劲松先生直接持股数量增至40,130,058股，占公司总股本的19.4143%。其一致行动人合计持股比例由25.4700%上升至25.4715%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000039622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688091"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787940106639,"stockEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.1005},{"period":"3month","weight":-0.1331},{"period":"6month","weight":-0.1867},{"period":"1year","weight":-0.4009},{"period":"ytd","weight":-0.1383}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.0323},{"period":"3month","weight":-0.0286},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0283},{"period":"ytd","weight":-0.0042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海谊众药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9868人(较上一季度增加4.97%)","perCapita":"20946股","listingDate":"2021-09-09","address":"上海市奉贤区仁齐路79号","registeredCapital":"20670万元","survey":" 上海谊众药业股份有限公司的主营业务是抗肿瘤创新药及相关产品的开发。公司的主要产品是抗肿瘤2类新药“注射用紫杉醇聚合物胶束”。","listedPrice":38.1},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海谊众(688091)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海谊众(688091)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海谊众,688091,上海谊众股票,上海谊众股票老虎,上海谊众股票老虎国际,上海谊众行情,上海谊众股票行情,上海谊众股价,上海谊众股市,上海谊众股票价格,上海谊众股票交易,上海谊众股票购买,上海谊众股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海谊众(688091)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海谊众(688091)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}